Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

DEA Seeks Assistance From PMP Programs in Establishing Aggregate Production Quotas

Posted 5/2/2023

The US Drug Enforcement Administration (DEA) has reached out the National Association of State Controlled Substances Authorities (NASCSA) to seek the assistance of state Prescription Monitoring Programs in establishing aggregate production quotas (APQs) for certain drugs as required by Congress.

The Drug Enforcement Administration (DEA) is required under the Controlled Substances Act (CSA) to establish aggregate production quotas (APQ) for each basic class of controlled substance in schedules I and II, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. Since 2021, NASCSA has played a pivotal role in DEA?s ability to comply with these statutory requirements. It is requested that State PDMP Administrators utilize the analytic tool provided by Bamboo Health to run the 2022 Aggregate Production Quota Report. Bamboo Health will provide assistance to states regarding questions related to report calculations and specifications. Please contact DEA would appreciate receiving responses from State PDMP Administrators no later than June 1, 2023, so the data may be considered in establishing the 2024 APQs. The reports and or any questions may be emailed to: and A direct request from the DEA will soon follow.

Back to all news

Sponsor Spotlight

COMPASS Pathways

COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more

All Sponsors